Hangzhou Bio-Sincerity Pharma-TechLtd Past Earnings Performance
Past criteria checks 1/6
Hangzhou Bio-Sincerity Pharma-TechLtd has been growing earnings at an average annual rate of 34.7%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 39.9% per year. Hangzhou Bio-Sincerity Pharma-TechLtd's return on equity is 7.7%, and it has net margins of 20.7%.
Key information
34.7%
Earnings growth rate
28.0%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 39.9% |
| Return on equity | 7.7% |
| Net Margin | 20.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability
Nov 04
Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)
Apr 29Recent updates
We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability
Nov 04Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward
Sep 30Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower
Jul 24Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)
Apr 29Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?
Mar 14Revenue & Expenses Breakdown
How Hangzhou Bio-Sincerity Pharma-TechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,025 | 212 | 120 | 321 |
| 30 Jun 24 | 1,119 | 287 | 172 | 298 |
| 31 Mar 24 | 1,072 | 287 | 156 | 260 |
| 31 Dec 23 | 1,017 | 272 | 159 | 240 |
| 30 Sep 23 | 900 | 250 | 155 | 203 |
| 30 Jun 23 | 786 | 229 | 153 | 184 |
| 31 Mar 23 | 673 | 210 | 131 | 164 |
| 01 Jan 23 | 607 | 194 | 113 | 163 |
| 30 Sep 22 | 573 | 192 | 93 | 149 |
| 30 Jun 22 | 479 | 155 | 75 | 120 |
| 31 Mar 22 | 425 | 126 | 70 | 110 |
| 31 Dec 21 | 374 | 111 | 62 | 78 |
| 30 Sep 21 | 304 | 101 | 51 | 51 |
| 30 Jun 21 | 267 | 85 | 48 | 44 |
| 31 Mar 21 | 211 | 55 | 46 | 36 |
| 31 Dec 20 | 207 | 57 | 50 | 32 |
| 31 Dec 19 | 156 | 44 | 35 | 15 |
| 31 Dec 18 | 82 | 11 | 23 | 12 |
| 31 Dec 17 | 26 | -7 | 10 | 8 |
| 30 Jun 17 | 30 | 8 | 11 | 0 |
| 31 Mar 17 | 27 | 5 | 11 | 0 |
| 31 Dec 16 | 24 | 3 | 12 | 0 |
| 30 Sep 16 | 21 | 1 | 12 | 0 |
| 30 Jun 16 | 16 | -1 | 11 | 0 |
| 31 Mar 16 | 16 | 2 | 8 | 0 |
| 01 Jan 16 | 16 | 5 | 4 | 0 |
| 31 Dec 14 | 6 | -2 | 4 | 0 |
Quality Earnings: 301096 has a high level of non-cash earnings.
Growing Profit Margin: 301096's current net profit margins (20.7%) are lower than last year (27.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301096's earnings have grown significantly by 34.7% per year over the past 5 years.
Accelerating Growth: 301096's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301096 had negative earnings growth (-15.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).
Return on Equity
High ROE: 301096's Return on Equity (7.7%) is considered low.